

Development of Parkinson's Disease Therapeutics through Degradation of Pathological α -Synuclein Protein Using the SPiDEM Platform

Prazer Therapeutics, Inc



PRAZER
THERAPEUTICS

NEUROLOGY	Lead
Product Type	Small molecule (targeted protein degrader)
Indication	Parkinson's disease
Target	α -synuclein
MoA(Mechanism of Action)	Alleviation of pathology through targeted degradation of pathological α -synuclein aggregates in neurons of Parkinson's disease brain
Competitiveness	First-in-class - No approved α -synuclein-targeted degrader - Good drug-likeness, compared to other TPD-based small molecules
Development Stage	Lead
Route of Administration	Oral administration